KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi, Paolo A Ascierto, Jun Guo, Ahmad A Tarhini, Sunandana Chandra, Eva Muñoz-Couselo, Michele Del Vecchio, Andreia Cristina de Melo, Margaret Callahan, Helen Gogas, Reinhard Dummer, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis Thomas, Jia Xin Yu, Andrew Fisher, Bonnie Wang, Patrick Djidel, Armand Chouzy, Mark Semaan, Bohang Chen, Alicia M Y Cheong, Hussein A Tawbi

Nat Med 31(12) 4301-4309

PMID41109920
PMCIDPMC12705465
DOI10.1038/s41591-025-04032-8
发表日期2025-10-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the phase 3, double-blind RELATIVITY-098 trial compared adjuvant nivolumab plus relatlimab to nivolumab after complete resection of stage III/IV melanoma. Patients were randomized 1:1 to receive nivolumab 480 mg plus relatlimab 160 mg (n = 547) or nivolumab 480 mg (n = 546) intravenously every 4 weeks for ≤1 year; safety populations totaled 543 and 545 patients, respectively. The primary endpoint was recurrence-free survival (RFS), and the key secondary was overall survival; translational endpoints were exploratory. There was no difference in RFS for nivolumab plus relatlimab versus nivolumab (hazard ratio = 1.01; 95% confidence interval: 0.83-1.22; P = 0.928); therefore, overall survival was not tested. Translational data across trials showed lower circulating LAG-3+ T cells in the adjuvant setting (RELATIVITY-098) versus advanced melanoma (RELATIVITY-047), where LAG-3+ T cells were enriched in tumor versus blood. The absence of macroscopic tumor and reduced peripheral LAG-3+ T cells may explain the lack of added benefit of nivolumab plus relatlimab over nivolumab in resected versus metastatic melanoma. ClinicalTrials.gov identifier: NCT05002569 .

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2. RFS and DMFS. a , Kaplan–Meier estimates of RFS defined as the time between randomization and the first date of documented recurrence (local, regional or distant recurrence or new primary melanomas (excluding in situ)) or death due to any cause in all randomized patients. b , DMFS defined as the time between randomization and first distant metastasis or death due to any cause in a subset of intention-to-treat patients, defined as those with resected stage III−IVA−IVB melanoma (those without presence of baseline metastasis prior to surgical resection—that is, stage III cutaneous and stage IVA−IVB mucosal melanoma). RFS statistical analysis was two-sided log-rank test, with no multiple comparisons. Symbols (circles) indicate censored data. Dashed lines indicate landmark analyses. CI, confidence interval; HR, hazard ratio; mDMFS, median DMFS; mRFS, median RFS; mo, months; NIVO, nivolumab; NR, not reached; RELA, relatlimab.

A

RFS

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
B

DMFS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Extended Data Fig. 1

Extended Data Fig. 1. OS. Kaplan–Meier estimates of OS defined as the time between randomization and death. Symbols (circles) indicate censored data. Dashed lines indicate landmark analyses. mOS, median OS; NIVO, nivolumab; NR, not reached; RELA, relatlimab.

OS

overall survival

Extended Data Fig. 1 · Panel OS

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel OS 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(8,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Flow diagram depicting the patient numbers in each arm throughout the study. CONSORT diagram. ITT, intention-to-treat.
非 KM Figure
Fig. 3Fig. 3. Pharmacodynamic and target engagement in the periphery for adjuvant treatment of melanoma. a , Expression of serum cytokines. b , Expression of surface LAG-3 + CD4 and CD8 T cells. c , Soluble LAG-3. a , Linear mixed-effect models per cytokine. Comparisons were between baseline and each on-treatment mean and of the mean of each arm for each timepoint. b , Linear mixed-effect models per flow populations. Comparisons of mean of each arm for each timepoint. c , Linear mixed-effect models for free soluble LAG-3. Comparisons were between baseline and each on-treatment mean and of the mean of each arm for each timepoint. Tests were two-sided t -tests for pairwise comparisons of estimated marginal means with 95% confidence interval (CI). No adjustment was made for multiple comparisons because each biomarker/timepoint was analyzed one at a time. NA, not applicable; NIVO, nivolumab; RELA relatlimab; wks, weeks.
非 KM Figure
Fig. 4Fig. 4. Comparative analysis of LAG-3 + and PD-1 + CD8 and CD4 T cells in metastatic and adjuvant treatment of melanoma. a , Baseline PD-1 + , LAG-3 + and PD-1 + LAG3 + CD8 cells in tumor and blood in advanced melanoma (RELATIVITY-047). b , Baseline expression of PD-1 + , LAG-3 + and PD-1 + LAG-3 + CD8 and CD4 cells in blood in advanced melanoma (RELATIVITY-047) and adjuvant-treated melanoma (RELATIVITY-098). c , Delta change of baseline to on-treatment expression of PD-1 + , LAG-3 + and PD-1 + LAG-3 + CD8 and CD4 cells in blood in advanced and adjuvant-treated melanoma. a , Tumor CD8 frequencies from CODEX/PhenoCycler. Blood frequencies from multiparametric flow cytometry. b , Figure is non-log mean and non-log median, and n is the number of patients with flow cytometry. Figure is the log-transformed frequencies of each population. c , Figure is non-log mean of delta and non-log median of delta, and n is the number of patients with flow cytometry. LAG-3 + and LAG-3 + PD-1 + figures represent the log-transformed frequencies of each population. Statistical tests were two-sided Wilcoxon tests with no multiple comparisons. Error bars are s.e. of the estimated marginal means.
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. RFS according to prespecified subgroups. Shown is a forest plot of hazard ratios for disease recurrence or death among prespecified subgroups of patients in the nivolumab plus relatlimab group and nivolumab group. The hazard ratios were not stratified according to the stratification factors. The horizontal lines indicate 95% confidence intervals with the hazard ratio represented by the center dot. AJCC-8, American Joint Committee on Cancer; Cancer Staging Manual , Eighth Edition; ECOG PS, Eastern Cooperative Oncology Group performance status; LAG-3, lymphocyte activation gene 3; LDH, lactate dehydrogenase; NIVO, nivolumab; RELA, relatlimab.
非 KM Figure
Extended Data Fig. 3Extended Data Fig. 3. Decrease in Soluble LAG-3 Levels Driven by Relatlimab Trough Concentration (Ctrough) Exposure. Center lines represent medians, the bounds of the boxes indicate the 25th and 75th percentiles, the whiskers represent the minima and maxima, and dots represent outliers; baseline = last non-missing result with a collection date-time less than or equal to the date-time of the first active dose of study medication; Q1 = [0.0892-8.7000); Q2 = [8.7000-13.2790); Q3 = [13.2790-19.5397); Q4 = [19.5397-50.5000].
非 KM Figure
Extended Data Fig. 4Extended Data Fig. 4. Pharmacodynamics Heat Map for Serum Factors in Patients with Melanoma treated with Adjuvant Nivolumab plus Relatlimab versus Nivolumab Alone in RELATIVITY-098. The figure presents a heatmap summarizing linear mixed effect models for a cytokine panel separated by treatment arm. Each individual box represents the statistical comparison between the on-treatment time point on the x-axis with the baseline time point, colored by the difference in means, in which blue is lower on treatment and red is higher on-treatment. C, cycle; D, day; ns, not significant/ P > 0.1. • P ≤ 0.1(trending), * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001.
非 KM Figure
Extended Data Fig. 5Extended Data Fig. 5. RFS Association with Baseline TME Biomarkers. a , Association with LAG-3 within treatment arms. b , Association with CD8 within treatment arms. c , Association with CD8 between treatment arms. CD8 density is defined as CD8 positive cells/mm 2 . Statistical testing is two-sided log-rank test with no multiple comparisons and error bars are 95% confidence interval. CD, cluster of differentiation; LAG-3, lymphocyte activation gene 3; TME, tumor microenvironment.
非 KM Figure
Extended Data Fig. 6Extended Data Fig. 6. Evaluation of CD8 and LAG-3 Biomarkers in Baseline and Recurrent Tumors. a , CD8 and LAG-3 expression overall in baseline vs early recurrent tumors. b , Baseline expression of CD8 and LAG-3 in patients who did not have a recurrence vs those who had an early recurrence (prior to the minimum follow-up of 23.4 months). a , Box plot of screening/baseline versus recurrent CD8% and LAG3% in pooled treatment arms. The figure shows each biomarker, visit, and frequency of patients below and above the 1% cutoff. b , Negative(n) indicates number of patients with <1% immunohistochemistry and N indicates number of patients with immunohistochemistry. Box plot shows 25%, 50% and 75% quartiles and statistical tests are two-sided Wilcoxon with no multiple comparisons.CD, cluster of differentiation; LAG-3, lymphocyte activation gene 3.
非 KM Figure